Siegfried Holding AGXSWX:SFZN -0.49%93 Return-on-Tangible-Equity is 20.38% as of Dec. 2025, which is 82% above its 10-year median of 11.20. GuruFocus rates XSWX:SFZN with a GF Score™ of 93/100 and a GF Value™ of CHF92.05 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 895 Drug Manufacturers companies, Siegfried Holding AG ranks better than 74.41% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Siegfried Holding AG's annualized net income for the quarter that ended in Dec. 2025 was CHF207 Mil. Siegfried Holding AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was CHF1,013 Mil. Therefore, Siegfried Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 20.38%.
The historical rank and industry rank for Siegfried Holding AG's Return-on-Tangible-Equity or its related term are showing as below:
XSWX:SFZN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.92 Med: 11.2 Max: 22.08
Current: 17.15
During the past 13 years, Siegfried Holding AG's highest Return-on-Tangible-Equity was 22.08%. The lowest was 4.92%. And the median was 11.20%.
XSWX:SFZN's Return-on-Tangible-Equity is ranked better than 74.41% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs XSWX:SFZN: 17.15
Siegfried Holding AG (XSWX:SFZN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Siegfried Holding AG Return-on-Tangible-Equity Related Terms
Siegfried Holding AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Siegfried Holding AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Siegfried Holding AG Return-on-Tangible-Equity Chart
XSWX:SFZN vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Siegfried Holding AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siegfried Holding AG Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Siegfried Holding AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Siegfried Holding AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.38% mean?
Siegfried Holding AG (XSWX:SFZN) has a Return-on-Tangible-Equity of 20.38% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Siegfried Holding AG and its competitors. This is 82% above median its historical median of 11.20. Over the past decade, Siegfried Holding AG's Return-on-Tangible-Equity has ranged from 4.92 to 22.08. According to the industry distribution chart, Siegfried Holding AG ranks #229 out of 895 companies in the Drug Manufacturers industry, placing it in the top 25.6%.
Is Siegfried Holding AG's Return-on-Tangible-Equity too high?
Siegfried Holding AG's current Return-on-Tangible-Equity of 20.38% is 82% above median its 10-year median of 11.20. Over the past 10 years, this metric has ranged from a low of 4.92 to a high of 22.08. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. Siegfried Holding AG's value of 20.38% is 158.3% above this industry median. Based on the distribution chart, Siegfried Holding AG ranks #229 out of 895 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Siegfried Holding AG has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Siegfried Holding AG's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Siegfried Holding AG ranks #229 out of 895 companies for Return-on-Tangible-Equity. This puts Siegfried Holding AG in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.89. Siegfried Holding AG's value of 20.38% is 158.3% above this benchmark. Historically, Siegfried Holding AG's own Return-on-Tangible-Equity has ranged from 4.92 to 22.08 over the past decade. While the company's 10-year median is 11.20 vs. the industry median of 7.89, Siegfried Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siegfried Holding AG's current Return-on-Tangible-Equity of 20.38% is 158.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Siegfried Holding AG and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siegfried Holding AG's current Return-on-Tangible-Equity is 20.38%, which is 82% above median its own 10-year median of 11.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siegfried Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Siegfried Holding AG (XSWX:SFZN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF92.05, compared to a current price of CHF71.80 — trading 22% below its estimated fair value. The current Return-on-Tangible-Equity is 20.38%, which is 82% above median its 10-year median of 11.20 and 158.3% above the Drug Manufacturers industry median of 7.89. Siegfried Holding AG's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Siegfried Holding AG (XSWX:SFZN), the current Return-on-Tangible-Equity is 20.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siegfried Holding AG (XSWX:SFZN) Overvalued in 2026?
Based on GuruFocus' analysis, Siegfried Holding AG stock appears to be undervalued.
The current stock price of CHF71.80 is trading 22% below its estimated GF Value™ of CHF92.05.
GuruFocus considers Siegfried Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:SFZN:
Return-on-Tangible-Equity: 20.38% (82% above median its 10-year median of 11.20)
GF Value™: CHF92.05 vs. price of CHF71.80 (22% below fair value)
Industry Position: 158.3% above the Drug Manufacturers median (#229 of 895)
No single metric tells the full story. See the XSWX:SFZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siegfried is a global contract development and manufacturing organization. It derives its revenue primarily from long-term supply agreements with biotechnology and pharmaceutical customers. Siegfried develops and manufactures active pharmaceutical ingredients, finished dosage forms (tablets, capsules, sterile vials, ampules, cartridges, and ointments), and viral vectors. The company provides these services throughout the entire drug lifecycle, including chemical and analytical development, pilot manufacturing, and commercial-scale manufacturing. Siegfried has a large global footprint with 13 production sites on three continents.
93GF Score
Get the complete analysis for XSWX:SFZN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SFZN has been successfully added to your 
